Inhibiting mTOR has been shown to suppress the growth of CD133+ pancreatic cancer stem cells and their sphere-forming ability, thereby confirming its role in self-renewal and CSC maintenance [186]. This evidence concerns the gene PROM1 and familial pancreatic carcinoma.